Global Breast Cancer Therapeutics Market Size, Share, Growth, Trends, Company Analysis and Forecast 2019-2026

The global Breast Cancer Therapeutics Market size will reach US$ 38,673.5 Mn by the end of 2026. If these figures prove true, the global Breast Cancer Therapeutics Market will rise at a CAGR of 10.7% between 2019 and 2026. Global breast cancer drugs market is expected to grow lucratively as many players focus majorly on R&D of innovative treatments. They engage in extensive research to develop novel drugs for the treatment of the disease to gain a higher market share. There exists a growing pressure and need for novel therapies and treatment due to rapidly accelerating prevalence of diseases. The strong pipeline is expected to provide new and effective treatment options and improved outcomes than existing therapies.

According to the World Health Organization, in 2018, an approximate of 627,000 women, which is tantamount to 15% of all cancer deaths worldwide, succumbed to breast cancer. The rising incidence of breast cancer is one of the chief drivers of the global Breast Cancer Therapeutics Market.

High Intake of Oral Contraceptives Among Women, Boosting Market

Breast cancer can develop due to reasons such as reduced breast feeding, rise in age of childbearing, undergoing estrogen modifying drug treatments and high intake of oral contraceptive pills. The increase in the number of women complaining of such problems and the successive rise in the number of breast cancer cases are factors boosting the global market for breast cancer therapeutics during the forecast period.

Another factor creating lucrative growth opportunities for breast cancer therapies is the increasing number of obese women. With change in lifestyle and unhealthy food habits, the rate of obesity is increasing by the day. Obesity further causes various health problems such as cardiovascular disorders, gall bladder diseases, diabetes, breathing problems, and breast cancer among others.

However, some breast cancer drugs may have serious side effects and this may act as a hindrance to the market. Besides this, countries that lack of awareness may restrict expansion of the market. Also social taboos prevalent in these countries may act as major deterrents to growth.

Nevertheless, the rate of demographic transition all around the world and advent of advanced diagnostic screening programs are creating growth opportunities for the market. Also government initiatives aimed at spreading awareness about breast cancer will bode well for the market.

North America to Remain Dominant on Account of Presence of Skilled Professionals

The breast cancer treatment market in North America is currently leading the global landscape, supported by the presence of a well-established healthcare infrastructure and rising uptake of advanced facilities in the region. In 2018, North America generated a revenue of US$ 8,033.8 Mn, because of the increasing prevalence of breast cancer in the region. In addition to this, the region boasts presence of several leading market players and skilled professionals. Besides this, governments of developed nations such as Canada and the U.S. are providing health insurance for cancer diagnostics. Spurred by these factors the Breast Cancer Therapeutics Market is likely to flourish in North America to emerge dominant.

Looming Patent Expiries Fuels Demand for Generic Drugs

The global Breast Cancer Therapeutics Market is likely to witness the prevalence of high competition. According to the report, Genentech, Inc. (F. Hoffmann-La Roche Ltd) held the dominant share in the market in 2018. Growth of the company is backed by its diverse product portfolio in targeted and chemotherapy segment.

With the expiry of most patent drugs in the market, there is an increased demand for their generic counterparts. Such factors are propelling vendors to invest more on research and development and develop generic drugs for breast cancer treatment. The introduction of combination drug therapy is anticipated to create better growth opportunities for the market.

Some of the major market players include F. Hoffmann-La Roche Ltd.; Novartis AG; AbbVie, Inc.; AstraZeneca; Eli Lilly and Company; Celgene Corporation; Biocon; Merck & Co., Inc.; Genzyme Corporation; Janssen Global services LLC; MacroGenics, Inc.; Celldex Therapeutics; Onyx Pharmaceuticals Inc.; and BioNumerik Pharmaceuticals, Inc.

New product developments, acquisitions, collaborations, and regional expansions are some of the key strategic initiatives undertaken by major players to maintain stability in the market. For instance, in March 2017, Kisqali received the Food and Drug Administration (FDA) approved HR+/HER2 as the first-line treatment for metastatic breast cancer in combination with an aromatase inhibitor. Kisqali is the only CDK 4/6 inhibitor approved for treatment of advanced stages of this disease in U.S.

For the study, the market has been segmented as follows:

Global Breast Cancer Therapeutics Market, by Drug Class

HER2 Inhibitors

• Herceptin (Trastuzumab)
• Tykerb (Lapatinib)
• Perjeta (Pertuzumab)
• Kadcyla (Ado-trastuzumab emtansine)

Mitotic Inhibitors

• Halaven (Eribulin)
• Taxotere (Docetaxel)
• Ixempra (Ixabepilone)

Anti-metabolites

• Gemzar (Gemcitabine)

Aromatase Inhibitors

• Femara (Leterozole)
• Aromasin (Exemestane)
• Arimidex (Anastrozole)
• Ibrance (Palbociclib)
• Afinitor (Everolimus)

Hormone Receptor

• Zoladex
• Faslodex
• Fareston

Global Breast Cancer Therapeutics Market, by Geography

• North America
  • S.
  • Canada
• Europe
  • Germany
  • K.
• Asia Pacific
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)